Announcement on the progress of entrusted financial management
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2017-031
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于委托理财进展情况的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 委托理财受托方:招商银行股份有限公司金华江北支行
l 委托理财金额:3000万元人民币
l 委托理财投资类型:保本浮动收益型结构性存款
l 委托理财期限:2017年10月10—2017年11月13日
一、本次委托理财概述
(一)本次委托理财的基本情况
公司于2017年10月10日与招商银行股份有限公司金华江北支行(以下简称“招商银行金华江北支行”)签署《招商银行单位结构性存款协议》,公司出资3,000万元人民币购买招商银行金华江北支行发售的单位结构性存款CHZ00318号理财产品,产品期限34天,预期年化收益率3.85%。本产品为保本浮动收益型理财产品。公司本次投资委托理财产品的资金来源为公司自有资金,且本次委托理财不构成关联交易。
(二)公司内部需履行的审批程序。
2015年4月17日,公司召开第九届董事会第2次会议审议通过了《关于授权公司董事长利用闲置自有资金进行委托理财等投资的议案》,授权公司董事长利用闲置自有资金进行委托理财等投资,最高不超过人民币1亿元,在该额度内资金可以滚动使用,每笔投资业务的期限均不得超过12个月。详见本公司在2015年4月21日在上海证券交易所网站披露的《关于授权董事长决定委托理财等投资的公告》(临2015-008)。
2017年8月25日,公司召开的第九届董事会第15次会议审议通过了《关于授权公司董事长决定委托理财的议案》。授权公司董事长行使不超过人民币2亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过2亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2017年8月29日在上海证券交易所网站披露的《关于授权董事长决定委托理财的公告》(临2017-024)。
公司本次购买招商银行金华江北支行结构性存款CHZ00318号理财产品,在公司第九届董事会第15次会议授权董事长决策范围之内。
二、本次委托理财协议主体的基本情况
1、交易对方名称:招商银行股份有限公司金华江北支行,公司类型:股份有限公司分公司(上市),营业场所:浙江省金华市婺城区解放东路268号莲花大夏附楼,负责人:胡刚,经营范围:经营总行在中国银行监督管理委员会批准的业务范围内授权的业务。
2、招商银行股份有限公司金华江北支行与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
三、 本次委托理财合同的主要内容
(一)基本说明
公司本次购买理财产品的资金来源为公司自有资金,委托理财期限为2017年10月10日至2017年11月13日。招商银行江北支行结构性存款产品为保本保底利息浮动收益型理财产品,预期年化收益率为3.85%,无需提供履约担保。本产品收益的计算中已包含(计入)银行的运营管理成本(如账户监管、资金运作管理、交易手续费等),公司无需支付或承担本产品下的其他费用或收费。
(二)产品说明
1、投资方向以及范围
结构性存款是指以企业的存款作为本金,挂钩利率、汇率、股票指数、商品价格等金融市场指标的创新型存款产品。如果投资方向正确,将获得额外收益;如果方向失误,将损失购买期权的费用,对于本金不造成影响。
2、收益计算
(1)本结构性存款产品到期日,由招商银行江北支行全额返还结构性存款本金及支付保底利率1.15%(年化)。
(2)本结构性存款产品收益兑付日,由招商银行江北支行根据预设条件支付结构性存款浮动收益。
(3)当发生政策风险或其他不可抗力因素时,收益保证条款不适用。
(4)浮动收益获得条件:如果存款存续期间内,伦敦金市下午定盘价在到期观察日未能突破波动区间【“期初价格-400美元”至“期初价格+400美元”(含边界)】,则本存款到期浮动利率2.7%(年化);如果存款存续期间内,伦敦金市下午定盘价在到期观察日突破波动区间【“期初价格-400美元”至“期初价格+400美元”(含边界)】,则本存款到期浮动利率为0。
(5)提前终止:本产品存续期内,公司与招商银行江北支行均无权提前终止本存款。
3、收益兑付
(1)本金及保底利息支付:结构性存款到期日,以转账方式将本金及保底利息转入公司原转存账户。
(2)收益支付:结构性存款收益兑付日,将浮动收益(如有)划入公司原转存帐户。
4、产品特点
该产品风险较小,适合对于利率、汇率、股票指数、商品价格等走势有一定见解和看法的投资人,并且为客户设置本金及保底利息保护,一定程度上降低了风险。
(三)敏感性分析
公司本次以自有资金3000万元购买的招商银行金华江北支行结构性存款CHZ00318号理财产品期限较短,不会对公司生产经营状况造成影响。在该投资期限内减少公司现金流净额3000万元,到期后预期为公司产生收益10.76万元。
(四)风险控制分析
本理财产品为保本收益型产品,银行确保公司本金安全,符合公司维护全体股东和公司利益的原则。公司始终将委托理财产品风险防控工作放在首位,严格按照内控制度有关规定,投资委托理财产品均为期限短、安全性高、流动性好的低风险银行理财产品。公司对购买的理财产品严格把关,谨慎决策。
四、截至本公告日,公司累计进行委托理财的金额。
(一)尚未到期的理财产品
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
|
1 |
广发银行金华分行 |
薪加薪16号J352人民币结构性存款产品 |
4,000.00 |
2017/7/28 |
2017/11/13 |
|
2 |
广发银行金华分行 |
薪加薪16号XJXCKJ0577人民币结构性存款产品 |
4,000.00 |
2017/9/14 |
2017/11/29 |
|
3 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00318 |
3,000.00 |
2017/10/10 |
2017/11/13 |
(二)连续十二个月内到期已收回本息的理财产品
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
截止公告日已收回本金金额(万元) |
截止公告日获得收益(万元) |
|
1 |
广发银行金华分行 |
薪加薪16号5876人民币结构性存款产品 |
5,000.00 |
2017/4/6 |
2017/7/5 |
5,000.00 |
51.16 |
|
2 |
渤海银行金华分行 |
渤海银行S17180号结构性存款理财产品 |
3,000.00 |
2017/5/17 |
2017/6/19 |
3,000.00 |
10.58 |
|
3 |
渤海银行金华分行 |
渤海银行S17265号结构性存款理财产品 |
3,000.00 |
2017/6/23 |
2017/7/27 |
3,000.00 |
12.30 |
|
4 |
广发银行金华分行 |
薪加薪16号J0253人民币结构性存款产品 |
4,000.00 |
2017/7/6 |
2017/10/9 |
4,000.00 |
44.66 |
(三)公司连续十二个月内累计委托理财金额
截止本公告日,公司连续十二个月内使用闲置自有资金进行委托理财的累计金额2.6亿元,其中:到期已收回1.5亿元,尚未到期的1.1亿元。
公司无其他未披露的委托理财事项。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一七年十月十二日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31